Jasper Therapeutics is trading 5.35% up now at $0.60 after presenting an expanded immunology strategy at the H.C. Wainwright conference on September 16, 2026.
- Approximately $140 million in cash supports operations through 2028, with upcoming venosabef milestones.
- Lisa Pitt and Shiguang Liu were announced in senior regulatory and clinical-development roles, reinforcing pipeline execution expectations.
- XBI down 2.11%; company-specific developments appear to offset weak biotech sentiment. No volume was provided; confidence is medium given aligned, not explicit, current-session attribution.